Entremed (ENMD)

[C_Peptide]

OT: re: Schwarz Pharma

Schwarz Pharma was at one time the lead company in the development of therapeutic C-peptide for the complications of type-1 diabetes, in partnership with the small Swedish biotech "Creative Peptides", however they have abandoned the partnership and Creative Peptides appears to be going it alone. I view Creative Peptides as a cousin of EntreMed, as they are also developing an endogenous molecule for the treatment of a chronic disease. Their Chief Scientific Officer, Dr. John Wahren, is the world leader in research into therapeutic C-peptide, as a review of the literature will show. About seven years ago I met with him to see if I could facilitate a clinical trial of C-peptide in Boston, but the time was not yet right. Schwarz thought they could improve on natural C-peptide with a synthetic analogue, but the project was abandoned. I owe my on-line name in large part to Dr. Wahren's research in to this missing part of hormone replacement therapy in type-1 diabetes.

Best Regards,
C-Peptide